celecoxib has been researched along with Hypertension in 71 studies
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 9.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 9.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis." | 9.01 | Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. ( Cooper-DeHoff, RM; Smith, SM, 2019) |
| "To explore the effects of celecoxib on pressure overload-induced cardiac hypertrophy (CH), cardiac dysfunction and explore the possible protective mechanisms." | 7.83 | Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress. ( Hao, F; Kang, Y; Liu, Y; Si, M; Su, L; Wang, F; Wang, H; Xin, X; Xu, J; Xue, F; Xue, M; Yu, L; Zhang, C; Zhang, Y, 2016) |
| "The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)." | 7.83 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016) |
| "Celecoxib significantly increased the incidence of new onset hypertension in this cohort of Indian patients with rheumatic diseases." | 7.79 | How safe is Celecoxib for Asian-Indian patients with rheumatic diseases? ( Chandra, C; Chandy, SJ; Danda, D; Iliyas, MM; Mathew, AJ, 2013) |
| "Results from a population-based cohort analysis of electronic medical records did not show any difference in the hazard rates of incident hypertension between celecoxib and NSNSAID users." | 7.74 | New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study. ( Mamdani, M; Mullins, CD; Rublee, DA; Shaya, FT; Wang, J, 2007) |
| "Domestic (US) cases of apparently unconfounded, acute hypertension leading to hospitalisation were collected and reviewed from the spontaneous adverse events database of the FDA for rofecoxib, celecoxib, nabumetone and oxaprozin for the initial 3 years of marketing." | 7.72 | Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. ( Beitz, J; Bonnel, R; Brinker, A; Goldkind, L, 2004) |
| " Recently, head-to-head, randomized, controlled trials have shown a significantly higher incidence of blood pressure (BP) destabilization and clinically significant edema with rofecoxib than with celecoxib among older, hypertensive patients with osteoarthritis (OA)." | 7.72 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003) |
| "Rofecoxib, but not celecoxib and NS NSAID, is associated with an increased risk of edema and blood pressure increase compared to nonusers of NSAID." | 7.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases." | 6.58 | Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. ( Angeli, F; Reboldi, G; Signorotti, S; Trapasso, M; Verdecchia, P, 2018) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 5.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| "In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62 ± 10 years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100-200 mg bid), ibuprofen (600-800 mg tid), or naproxen (375-500 mg bid) with matching placebos in a 1: 1: 1 allocation, to assess the effect on 24-h ambulatory BP after 4 months." | 5.24 | Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) ( Beckerman, B; Borer, JS; Davey, DA; Fayyad, R; Flammer, AJ; Graham, DY; Husni, ME; Iorga, D; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wisniewski, LM; Yeomans, ND, 2017) |
| "Aliskiren is the first in a new class of orally effective direct renin inhibitors approved for the treatment of hypertension." | 5.13 | A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. ( Ayalasomayajula, S; Bizot, MN; Dieterich, HA; Dole, WP; Howard, D; Tchaloyan, S; Yeh, CM, 2008) |
| "Aliskiren is the first in a new class of orally effective renin inhibitors for the treatment of hypertension." | 5.11 | Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. ( Corynen, S; Dieterle, W; Mann, J; Vaidyanathan, S, 2005) |
| "At equally effective doses for osteoarthritis management, treatment with rofecoxib but not celecoxib or naproxen induced a significant increase in 24-hour systolic BP." | 5.11 | The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. ( Brabant, T; Fort, JG; Kivitz, A; Pitt, B; Simon, LS; Sowers, JR; van Ingen, H; Whelton, A; White, WB; Winer, N, 2005) |
| "To evaluate the relative gastrointestinal (GI) tolerability of celecoxib and rofecoxib in elderly hypertensive patients with osteoarthritis (OA) with or without coadministration of low dose aspirin (ASA) (< or = 325 mg daily)." | 5.11 | Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials. ( Bello, AE; Fort, JG; Goldstein, JL; Spalding, W; Suh, S, 2005) |
| " The objective of this study was to determine the effects of celecoxib compared with placebo on 24-hour BP levels in ACE inhibitor-treated patients with hypertension." | 5.10 | Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. ( Kent, J; Lefkowith, JB; Taylor, A; Verburg, KM; Whelton, A; White, WB, 2002) |
| " This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens." | 5.10 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. ( Bello, AE; Fort, JG; Puma, JA; Whelton, A; White, WB, 2002) |
| "The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis." | 5.01 | Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. ( Cooper-DeHoff, RM; Smith, SM, 2019) |
| " Key search terms included COX-2 selective inhibitors; anti-inflammatory agents, nonsteroidal; celecoxib; rofecoxib; and hypertension." | 4.82 | Effect of cyclooxygenase-2 inhibitors on blood pressure. ( Hisel, TM; Johnson, DL; Phillips, BB, 2003) |
| "The novel cyclooxygenase- (COX)-2 inhibitor celecoxib is an effective treatment for the signs and symptoms of osteoarthritis and rheumatoid arthritis." | 4.80 | Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. ( Geis, GS; Maurath, CJ; Verburg, KM; Whelton, A, 2000) |
| "To explore the effects of celecoxib on pressure overload-induced cardiac hypertrophy (CH), cardiac dysfunction and explore the possible protective mechanisms." | 3.83 | Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress. ( Hao, F; Kang, Y; Liu, Y; Si, M; Su, L; Wang, F; Wang, H; Xin, X; Xu, J; Xue, F; Xue, M; Yu, L; Zhang, C; Zhang, Y, 2016) |
| "The aim of the study is to assess the effects of celecoxib and sulfasalazine on the risk of coronary artery disease (CAD) in patients with ankylosing spondylitis (AS)." | 3.83 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study. ( Chiou, JY; Leong, PY; Li, TY; Wang, YH; Wei, JC; Wu, LC; Yeo, KJ, 2016) |
| "Celecoxib significantly increased the incidence of new onset hypertension in this cohort of Indian patients with rheumatic diseases." | 3.79 | How safe is Celecoxib for Asian-Indian patients with rheumatic diseases? ( Chandra, C; Chandy, SJ; Danda, D; Iliyas, MM; Mathew, AJ, 2013) |
| "Apocynin, Mito-TEMPO, and Celecoxib treatments prevented Ang II-induced hypertension, the increased vasoconstrictor responses to phenylephrine, and the reduced acetylcholine relaxation." | 3.79 | Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. ( Aguado, A; Alonso, MJ; Alvarez, Y; Avendaño, MS; Briones, AM; Esteban, V; García-Redondo, AB; García-Redondo, L; Martínez-Revelles, S; Pérez-Girón, JV; Redondo, JM; Salaices, M, 2013) |
| " The results show that lack of SphK1 expression did not exacerbate angiotensin II (Ang II)-induced acute hypertension, whereas celecoxib, a COX-2 inhibitor, augmented and sustained higher BP in mice." | 3.79 | Effect of sphingosine kinase 1 inhibition on blood pressure. ( Furuya, H; Hannun, YA; Kawamori, T; Obeid, LM; Shimizu, Y; Wada, M; Yamada, PM, 2013) |
| "This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary artery disease." | 3.77 | Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. ( Bavry, AA; Cooper-Dehoff, RM; Gong, Y; Handberg, EM; Khaliq, A; Pepine, CJ, 2011) |
| "the purpose of the present work was to investigate the effect of cyclooxygenase-2 (COX-2) inhibition on the cardiovascular and inflammatory aspects promoted by monosodium glutamate (MSG)-induced obesity in rats." | 3.76 | Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats. ( Cecchini, R; Cunha, NV; de Abreu, SB; Grassiolli, S; Guarnier, FA; Martins-Pinge, MC; Mazzuco, TL; Panis, C; Pinge-Filho, P, 2010) |
| "Results from a population-based cohort analysis of electronic medical records did not show any difference in the hazard rates of incident hypertension between celecoxib and NSNSAID users." | 3.74 | New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study. ( Mamdani, M; Mullins, CD; Rublee, DA; Shaya, FT; Wang, J, 2007) |
| "In view of the ongoing controversy of cardiorenal safety of selective COX-2 inhibitors (coxibs), the present study was designed to examine the effects of 2 different coxibs, celecoxib and rofecoxib, compared with a traditional NSAID, diclofenac, and placebo on renal morphology and function in salt-sensitive hypertension." | 3.73 | Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. ( Bühler, N; Camici, G; Chenevard, R; Gröne, HJ; Hermann, M; Kiss, E; Lüscher, TF; Ruschitzka, F; Shaw, S, 2005) |
| "Switching patients from celecoxib to rofecoxib resulted in an increase in BP, with a larger difference observed in patients with hypertension." | 3.73 | Blood pressure in Native Americans switched from celecoxib to rofecoxib. ( Diggins, DA; Fredy, J; Morrill, GB, 2005) |
| "Domestic (US) cases of apparently unconfounded, acute hypertension leading to hospitalisation were collected and reviewed from the spontaneous adverse events database of the FDA for rofecoxib, celecoxib, nabumetone and oxaprozin for the initial 3 years of marketing." | 3.72 | Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin. ( Beitz, J; Bonnel, R; Brinker, A; Goldkind, L, 2004) |
| " Recently, head-to-head, randomized, controlled trials have shown a significantly higher incidence of blood pressure (BP) destabilization and clinically significant edema with rofecoxib than with celecoxib among older, hypertensive patients with osteoarthritis (OA)." | 3.72 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population. ( Becker, RV; Burke, TA; McCoy, MA; Trotter, JP, 2003) |
| "Rofecoxib, but not celecoxib and NS NSAID, is associated with an increased risk of edema and blood pressure increase compared to nonusers of NSAID." | 3.72 | Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. ( Pettitt, D; Wolfe, F; Zhao, S, 2004) |
| "These findings suggest a higher risk of admission for congestive heart failure in users of rofecoxib and non-selective NSAIDs, but not celecoxib, relative to non-NSAID controls." | 3.72 | Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. ( Austin, PC; Juurlink, DN; Kopp, A; Laupacis, A; Lee, DS; Mamdani, M; Naglie, G; Rochon, PA; Stukel, TA, 2004) |
| " Rofecoxib taken at supra-therapeutic dosage was recognised to increase the incidence of myocardial infarction." | 3.72 | [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period]. ( Lamarque, D, 2004) |
| "These data show that celecoxib but not rofecoxib or diclofenac improves endothelial dysfunction and reduces oxidative stress, thus pointing to differential effects of coxibs in salt-induced hypertension." | 3.72 | Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. ( Camici, G; Fiedler, M; Fratton, A; Gay, RE; Gay, S; Hellermann, JP; Hermann, M; Hurlimann, D; Lüscher, TF; Neidhart, M; Ruschitzka, F; Tanner, FC; Thiery, J, 2003) |
| "To determine the costs of heart failure in hypertensive patients receiving celecoxib, rofecoxib, and nonspecific nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice." | 3.71 | Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors. ( Burke, TA; Henderson, SC; von Allmen, H; Whelton, A; Zhao, SZ, 2002) |
| "The aim of this study was to describe physician-reported management of clinically significant edema and/or destabilized blood pressure in patients with osteoarthritis (OA) and hypertension when initiating therapy with rofecoxib or celecoxib." | 3.71 | Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension. ( Bristol, S; Burke, TA; May, C; Osterhaus, JT; Wentworth, C; Whelton, A, 2002) |
| " Normal rats and rats with hypertension induced by chronic administration of Nomega-nitro-L-arginine methylester were given celecoxib (10 mg kg(-1)) daily for 3 weeks." | 3.70 | Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. ( Asfaha, S; Elliott, SN; Lovren, F; Muscará, MN; Triggle, CR; Vergnolle, N; Wallace, JL, 2000) |
| "Chronic pain is associated with impaired regulation of cardiovascular and analgesia systems, which may predispose to persistent BP elevation." | 2.82 | The Effects of Pain and Analgesic Medications on Blood Pressure. ( Coscarelli, A; Giordano, A; Menale, S; Rivasi, G; Turrin, G; Ungar, A, 2022) |
| "Rofecoxib caused an increase in BP compared to celecoxib; a change in recumbent systolic BP +/- SD (6." | 2.72 | Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels? ( Aw, TJ; Billah, B; Krum, H; Liew, D; Morel-Kopp, MC; Schneider, HG; Tofler, GH, 2006) |
| " Differences observed in blood pressure response between COX inhibitors may not be related in their sensitivity but rather their dosing frequency." | 2.71 | Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. ( Alausa, T; Bakris, GL; Folker, A; Hung, E; Izhar, M, 2004) |
| "Hypertension is associated with endothelial dysfunction that is attributable to oxidative stress and a proinflammatory state." | 2.71 | Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. ( Duffy, SJ; Eberhardt, RT; Gokce, N; Holbrook, M; Keaney, JF; Maxwell, C; Morrow, JD; Palmisano, J; Price, DT; Vita, JA; Widlansky, ME, 2003) |
| "Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases." | 2.58 | Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. ( Angeli, F; Reboldi, G; Signorotti, S; Trapasso, M; Verdecchia, P, 2018) |
| "Celecoxib and SC19220 treatment did not modify the altered lumen diameter and wall : lumen ratio in mesenteric resistance arteries from SHR-infused and/or AngII-infused animals." | 1.43 | Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension. ( Aguado, A; Alonso, MJ; Avendaño, MS; Beltrán, LM; Briones, AM; Cachofeiro, MV; García-Puig, J; González-Amor, M; Guillem-Llobat, P; Martínez-Revelles, S; Palacios, R; Salaices, M; Simões, MR; Vassallo, DV; Vila, L, 2016) |
| "CSA hypertension was associated with renal perivascular fibrosis and divergent changes in immunohistochemical signals of renal arteriolar ETA (increases) and ETB (decreases) receptors." | 1.42 | Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling. ( Ali, RM; El-Gowelli, HM; El-Mas, MM; Helmy, MW, 2015) |
| "Ibuprofen was associated with a 3 mmHg increase in systolic blood pressure compared to naproxen (95% CI, 0." | 1.38 | Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension. ( Aljadhey, H; Blalock, SJ; Brater, DC; Hansen, RA; Murray, MD; Tu, W, 2012) |
| "The psoriatic arthritis was treated with celecoxib and multiple sclerosis with fingolimod." | 1.38 | A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart? ( Cocco, G, 2012) |
| " The present study investigated the importance of endogenous prostaglandin production and nitric oxide (NO) in the renal haemodynamic and excretory responses to ischaemia-reperfusion both normally and in the hypertensive state by chronic administration of cyclo-oxygenase (COX) inhibitors." | 1.35 | Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation. ( Johns, EJ; Knight, S, 2008) |
| "Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by symmetrical sclerodermatous skin changes primarily affecting the extremities and histologically, by thickening of the fascia with chronic inflammatory infiltrate containing eosinophils." | 1.34 | Eosinophilic fasciitis in a 57-year-old Japanese-American woman. ( Ambrocio, DU; Uramoto, K, 2007) |
| "Osteoarthritis and hypertension are highly prevalent among older Americans." | 1.33 | Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? ( Coupal, L; Grover, SA; Zowall, H, 2005) |
| " However, significantly more rofecoxib-treated patients had the dosage of their existing antihypertensive drug increased compared with those receiving celecoxib." | 1.32 | Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib. ( Dickerson, LM; Nietert, PJ; Ornstein, SM; Rothenberg, RJ, 2003) |
| "Rofecoxib users were at a significantly increased relative risk of new onset hypertension compared with patients taking celecoxib (odds ratio [OR] 1." | 1.32 | Relationship between COX-2 specific inhibitors and hypertension. ( Avorn, J; Levin, R; Schneeweiss, S; Solomon, DH, 2004) |
| " The drug's effect as well as adverse effects should be actively sought, and dosage alterations made in order to enhance the drug's effect." | 1.32 | Introduction to monitoring. What is what you prescribed actually doing? ( George, A; Shakib, S, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 45 (63.38) | 29.6817 |
| 2010's | 22 (30.99) | 24.3611 |
| 2020's | 4 (5.63) | 2.80 |
| Authors | Studies |
|---|---|
| Rivasi, G | 1 |
| Menale, S | 1 |
| Turrin, G | 1 |
| Coscarelli, A | 1 |
| Giordano, A | 1 |
| Ungar, A | 1 |
| Piszczatoski, CR | 1 |
| Smith, SM | 2 |
| Hofferer, A | 1 |
| Dolladille, C | 1 |
| Chretien, B | 1 |
| Sassier, M | 1 |
| Laugier, D | 1 |
| Atzenhoffer, M | 1 |
| Bagheri, H | 1 |
| Alexandre, J | 1 |
| Fedrizzi, S | 1 |
| Humbert, X | 1 |
| Ruschitzka, F | 3 |
| Borer, JS | 1 |
| Krum, H | 2 |
| Flammer, AJ | 1 |
| Yeomans, ND | 1 |
| Libby, P | 1 |
| Lüscher, TF | 3 |
| Solomon, DH | 2 |
| Husni, ME | 1 |
| Graham, DY | 1 |
| Davey, DA | 1 |
| Wisniewski, LM | 1 |
| Menon, V | 1 |
| Fayyad, R | 1 |
| Beckerman, B | 1 |
| Iorga, D | 1 |
| Lincoff, AM | 1 |
| Nissen, SE | 1 |
| Dong, YH | 1 |
| Chang, CH | 1 |
| Wu, LC | 2 |
| Hwang, JS | 1 |
| Toh, S | 1 |
| Cooper-DeHoff, RM | 2 |
| Angeli, F | 1 |
| Trapasso, M | 1 |
| Signorotti, S | 1 |
| Verdecchia, P | 1 |
| Reboldi, G | 1 |
| Shukla, AK | 1 |
| Jhaj, R | 1 |
| Danda, D | 1 |
| Iliyas, MM | 1 |
| Chandy, SJ | 1 |
| Chandra, C | 1 |
| Mathew, AJ | 1 |
| El-Mas, MM | 1 |
| Helmy, MW | 1 |
| Ali, RM | 1 |
| El-Gowelli, HM | 1 |
| Zhang, C | 1 |
| Wang, F | 1 |
| Zhang, Y | 1 |
| Kang, Y | 1 |
| Wang, H | 1 |
| Si, M | 1 |
| Su, L | 1 |
| Xin, X | 1 |
| Xue, F | 1 |
| Hao, F | 1 |
| Yu, L | 1 |
| Xu, J | 1 |
| Liu, Y | 1 |
| Xue, M | 1 |
| Avendaño, MS | 2 |
| Martínez-Revelles, S | 2 |
| Aguado, A | 2 |
| Simões, MR | 1 |
| González-Amor, M | 1 |
| Palacios, R | 1 |
| Guillem-Llobat, P | 1 |
| Vassallo, DV | 1 |
| Vila, L | 1 |
| García-Puig, J | 1 |
| Beltrán, LM | 1 |
| Alonso, MJ | 2 |
| Cachofeiro, MV | 1 |
| Salaices, M | 2 |
| Briones, AM | 2 |
| Leong, PY | 1 |
| Yeo, KJ | 1 |
| Li, TY | 1 |
| Wang, YH | 1 |
| Chiou, JY | 1 |
| Wei, JC | 1 |
| Li, Y | 1 |
| Tian, D | 1 |
| Zhu, C | 1 |
| Ren, L | 1 |
| Simon, LS | 2 |
| White, WB | 5 |
| Raynauld, JP | 1 |
| Martel-Pelletier, J | 1 |
| Beaulieu, A | 1 |
| Bessette, L | 1 |
| Morin, F | 1 |
| Choquette, D | 1 |
| Haraoui, B | 1 |
| Abram, F | 1 |
| Pelletier, JP | 1 |
| Elliott, WJ | 1 |
| Cunha, NV | 1 |
| de Abreu, SB | 1 |
| Panis, C | 1 |
| Grassiolli, S | 1 |
| Guarnier, FA | 1 |
| Cecchini, R | 1 |
| Mazzuco, TL | 1 |
| Pinge-Filho, P | 1 |
| Martins-Pinge, MC | 1 |
| Triadafilopoulos, G | 1 |
| Lombard, CM | 1 |
| Jobe, BA | 1 |
| Bavry, AA | 1 |
| Khaliq, A | 1 |
| Gong, Y | 1 |
| Handberg, EM | 1 |
| Pepine, CJ | 1 |
| Soloviev, MA | 1 |
| Kulakova, NV | 1 |
| Semiglazova, TA | 1 |
| Borodulina, EV | 1 |
| Udut, VV | 1 |
| Blackler, R | 1 |
| Syer, S | 1 |
| Bolla, M | 1 |
| Ongini, E | 1 |
| Wallace, JL | 2 |
| Cocco, G | 1 |
| García-Redondo, AB | 1 |
| Alvarez, Y | 1 |
| Pérez-Girón, JV | 1 |
| García-Redondo, L | 1 |
| Esteban, V | 1 |
| Redondo, JM | 1 |
| Aljadhey, H | 1 |
| Tu, W | 1 |
| Hansen, RA | 1 |
| Blalock, SJ | 1 |
| Brater, DC | 1 |
| Murray, MD | 1 |
| Furuya, H | 1 |
| Wada, M | 1 |
| Shimizu, Y | 1 |
| Yamada, PM | 1 |
| Hannun, YA | 1 |
| Obeid, LM | 1 |
| Kawamori, T | 1 |
| Osterhaus, JT | 1 |
| Burke, TA | 4 |
| May, C | 1 |
| Wentworth, C | 1 |
| Whelton, A | 7 |
| Bristol, S | 1 |
| Bello, AE | 2 |
| Puma, JA | 1 |
| Fort, JG | 3 |
| Zhao, SZ | 2 |
| von Allmen, H | 2 |
| Henderson, SC | 2 |
| LeLorier, J | 1 |
| Bombardier, C | 1 |
| Burgess, E | 1 |
| Moist, L | 1 |
| Wright, N | 1 |
| Cartier, P | 1 |
| Huckell, V | 1 |
| Hunt, R | 1 |
| Nawar, T | 1 |
| Tobe, S | 1 |
| Palmer, R | 1 |
| Weiss, R | 1 |
| Zusman, RM | 1 |
| Haig, A | 1 |
| Flavin, S | 1 |
| MacDonald, B | 1 |
| Harley, C | 1 |
| Wagner, S | 1 |
| Johnson, DL | 1 |
| Hisel, TM | 1 |
| Phillips, BB | 1 |
| Cheng, TO | 1 |
| Weaver, A | 1 |
| Alderman, M | 1 |
| Sperling, R | 1 |
| Becker, RV | 1 |
| McCoy, MA | 1 |
| Trotter, JP | 1 |
| Tsurko, VV | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Ob ukhova, OA | 1 |
| Widlansky, ME | 1 |
| Price, DT | 1 |
| Gokce, N | 1 |
| Eberhardt, RT | 1 |
| Duffy, SJ | 1 |
| Holbrook, M | 1 |
| Maxwell, C | 1 |
| Palmisano, J | 1 |
| Keaney, JF | 1 |
| Morrow, JD | 1 |
| Vita, JA | 1 |
| Shakib, S | 1 |
| George, A | 1 |
| Hermann, M | 2 |
| Camici, G | 2 |
| Fratton, A | 1 |
| Hurlimann, D | 1 |
| Tanner, FC | 1 |
| Hellermann, JP | 1 |
| Fiedler, M | 1 |
| Thiery, J | 1 |
| Neidhart, M | 1 |
| Gay, RE | 1 |
| Gay, S | 1 |
| Nietert, PJ | 1 |
| Ornstein, SM | 1 |
| Dickerson, LM | 1 |
| Rothenberg, RJ | 1 |
| Izhar, M | 1 |
| Alausa, T | 1 |
| Folker, A | 1 |
| Hung, E | 1 |
| Bakris, GL | 1 |
| Brinker, A | 1 |
| Goldkind, L | 1 |
| Bonnel, R | 1 |
| Beitz, J | 1 |
| Wolfe, F | 1 |
| Zhao, S | 1 |
| Pettitt, D | 1 |
| Mamdani, M | 2 |
| Juurlink, DN | 1 |
| Lee, DS | 1 |
| Rochon, PA | 1 |
| Kopp, A | 1 |
| Naglie, G | 1 |
| Austin, PC | 1 |
| Laupacis, A | 1 |
| Stukel, TA | 1 |
| Schneeweiss, S | 1 |
| Levin, R | 1 |
| Avorn, J | 1 |
| Lamarque, D | 1 |
| Grover, SA | 1 |
| Coupal, L | 1 |
| Zowall, H | 1 |
| Chang, IJ | 1 |
| Harris, RC | 1 |
| Shaw, S | 1 |
| Kiss, E | 1 |
| Bühler, N | 1 |
| Chenevard, R | 1 |
| Gröne, HJ | 1 |
| Goldstein, JL | 1 |
| Spalding, W | 1 |
| Suh, S | 1 |
| Sowers, JR | 1 |
| Pitt, B | 1 |
| Winer, N | 1 |
| Kivitz, A | 1 |
| van Ingen, H | 1 |
| Brabant, T | 1 |
| Fredy, J | 1 |
| Diggins, DA | 1 |
| Morrill, GB | 1 |
| Durrieu, G | 1 |
| Olivier, P | 1 |
| Montastruc, JL | 1 |
| Dieterle, W | 1 |
| Corynen, S | 1 |
| Vaidyanathan, S | 1 |
| Mann, J | 1 |
| Tegeder, I | 1 |
| Geisslinger, G | 1 |
| Aw, TJ | 1 |
| Liew, D | 1 |
| Tofler, GH | 1 |
| Schneider, HG | 1 |
| Morel-Kopp, MC | 1 |
| Billah, B | 1 |
| Valat, JP | 1 |
| Deray, G | 1 |
| Héloire, F | 1 |
| Ambrocio, DU | 1 |
| Uramoto, K | 1 |
| Wang, J | 1 |
| Mullins, CD | 1 |
| Rublee, DA | 1 |
| Shaya, FT | 1 |
| Knight, S | 1 |
| Johns, EJ | 1 |
| Ayalasomayajula, S | 1 |
| Tchaloyan, S | 1 |
| Yeh, CM | 1 |
| Bizot, MN | 1 |
| Dieterich, HA | 1 |
| Howard, D | 1 |
| Dole, WP | 1 |
| Bangalore, S | 1 |
| Khianey, S | 1 |
| Messerli, FH | 1 |
| Muscará, MN | 1 |
| Vergnolle, N | 1 |
| Lovren, F | 1 |
| Triggle, CR | 1 |
| Elliott, SN | 1 |
| Asfaha, S | 1 |
| Maurath, CJ | 1 |
| Verburg, KM | 2 |
| Geis, GS | 1 |
| Fleming, M | 1 |
| Kent, J | 1 |
| Taylor, A | 1 |
| Lefkowith, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| Influence of the Autonomic Nervous System on Endothelial Function as an Acute Response to Exercise in Hypertensive Individuals: a Randomized Double-blind Protocol Study[NCT04371757] | 39 participants (Anticipated) | Interventional | 2020-04-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
12 reviews available for celecoxib and Hypertension
| Article | Year |
|---|---|
The Effects of Pain and Analgesic Medications on Blood Pressure.
Topics: Acetaminophen; Adrenergic Agents; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Ster | 2022 |
Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.
Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Humans; Hyp | 2019 |
Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.
Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Drug Combin | 2018 |
COX-2 selective inhibitors and heart health.
Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; | 2005 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Dic | 2010 |
Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Interactions; Gl | 2002 |
Effect of cyclooxygenase-2 inhibitors on blood pressure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2003 |
[Interactions of nonsteroid anti-inflammatory drugs with inhibitors of angiotensin-converting enzyme in patients with rheumatic diseases (a review)].
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheuma | 2003 |
Are all COX-2 inhibitors created equal?
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Hype | 2005 |
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?
Topics: Cardiovascular Diseases; Celecoxib; Cell Proliferation; Clinical Trials as Topic; Cyclooxygenase Inh | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal | 2000 |
12 trials available for celecoxib and Hypertension
| Article | Year |
|---|---|
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement)
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Coronary | 2017 |
Correction of endothelial dysfunction in patients with arterial hypertension.
Topics: Aspirin; Biomarkers; C-Reactive Protein; Celecoxib; Cyclooxygenase Inhibitors; Endothelium, Vascular | 2011 |
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; | 2002 |
Effects of nabumetone, celecoxib, and ibuprofen on blood pressure control in hypertensive patients on angiotensin converting enzyme inhibitors.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Bloo | 2003 |
Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension.
Topics: Adult; Analysis of Variance; Blood Pressure; Brachial Artery; Celecoxib; Cyclooxygenase 2; Cyclooxyg | 2003 |
Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2004 |
Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
Topics: Aspirin; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method | 2005 |
The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Blood Glucose; Blood Pressure Determi | 2005 |
Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Amides; Atenolol; Celecoxib; Cimetidine; Cross-Over | 2005 |
Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
Topics: Aged; Aldosterone; Blood Pressure; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Femal | 2006 |
A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Topics: Adolescent; Adult; Allopurinol; Amides; Antihypertensive Agents; Celecoxib; Cimetidine; Cyclooxygena | 2008 |
Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Ste | 2002 |
47 other studies available for celecoxib and Hypertension
| Article | Year |
|---|---|
Consensi --a fixed dose combination of amlodipine and celecoxib.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Celecoxib; Cyclooxygenase 2 Inhibitor | 2020 |
Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Celecoxib; Drug Combinations; Humans; Hypertens | 2021 |
[Antidepressive agents and hypertension: A case/no-case study in French pharmacovigilance database].
Topics: Acetaminophen; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Celecoxib; Humans; Hy | 2022 |
Comparative cardiovascular safety of nonsteroidal anti-inflammatory drugs in patients with hypertension: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Cyclooxygenase 2 In | 2018 |
Consensi: Is it a conscientious combination?
Topics: Amlodipine; Antihypertensive Agents; Arthralgia; Blood Pressure; Celecoxib; Clinical Trials as Topic | 2019 |
How safe is Celecoxib for Asian-Indian patients with rheumatic diseases?
Topics: Adult; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Drug Substitution; Female; Humans; Hyperten | 2013 |
Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclosporine; Cytoprote | 2015 |
Celecoxib prevents pressure overload-induced cardiac hypertrophy and dysfunction by inhibiting inflammation, apoptosis and oxidative stress.
Topics: Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Celecoxib; Cell Survival; Cyclooxygenase 2 Inh | 2016 |
Role of COX-2-derived PGE2 on vascular stiffness and function in hypertension.
Topics: Animals; Celecoxib; Cells, Cultured; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dibenz(b,f)(1,4) | 2016 |
Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Case-Control Studies; Celecoxib; Coronary Artery Dis | 2016 |
Demethoxycurcumin Preserves Renovascular Function by Downregulating COX-2 Expression in Hypertension.
Topics: Acetylcholine; Aged; Angiotensin II; Animals; Blood Pressure; Celecoxib; Curcuma; Curcumin; Cyclooxy | 2016 |
An open-label pilot study evaluating by magnetic resonance imaging the potential for a disease-modifying effect of celecoxib compared to a modelized historical control cohort in the treatment of knee osteoarthritis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Cohort Studies; Cycl | 2010 |
Cox-2 inhibition attenuates cardiovascular and inflammatory aspects in monosodium glutamate-induced obese rats.
Topics: Adipose Tissue; Animals; Blood; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2010 |
"War and Peace" with Barrett's esophagus.
Topics: Adenocarcinoma; Aged; Anti-Ulcer Agents; Antihypertensive Agents; Aspirin; Barrett Esophagus; Celeco | 2011 |
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celec | 2011 |
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Aspirin; Celecoxib; Drug Therapy, Combi | 2012 |
A patient with Leiden V mutation, multiple sclerosis, psoriasis, and sicca syndrome: could celecoxib and fingolimod adversely affect the heart?
Topics: Arthritis, Psoriatic; Atrial Fibrillation; Autoimmune Diseases; Celecoxib; Cyclooxygenase Inhibitors | 2012 |
Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension.
Topics: Acetophenones; Animals; Antioxidants; Aorta; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxy | 2013 |
Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive A | 2012 |
Effect of sphingosine kinase 1 inhibition on blood pressure.
Topics: Animals; Base Sequence; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Di | 2013 |
Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension.
Topics: Celecoxib; Cross-Sectional Studies; Cyclooxygenase Inhibitors; Diuretics; Edema; Humans; Hypertensio | 2002 |
Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cross-Sectional S | 2002 |
Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2002 |
The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular D | 2003 |
Anti-inflammatory drugs may put on the pressure.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase Inhibitors; Human | 2003 |
No success with the SUCCESS trial.
Topics: Abbreviations as Topic; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; | 2003 |
Blood pressure control and rates of edema following the administration of the cyclooxygenase-2 specific inhibitors celecoxib versus rofecoxib in patients with systemic hypertension and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; Cycloox | 2003 |
A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Costs and Cost Analysis; C | 2003 |
Introduction to monitoring. What is what you prescribed actually doing?
Topics: Acetaminophen; Aged; Aspirin; Australia; Celecoxib; Drug Interactions; Drug Therapy, Combination; Fa | 2003 |
Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Topics: Acetylcholine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cycloo | 2003 |
Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antihypertensive Agents; Blood Pressure; Celecoxib; Chi-Sq | 2003 |
Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2004 |
Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecox | 2004 |
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase Inhibitors; | 2004 |
Hypertension associated with therapies to treat arthritis and pain.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agent | 2004 |
Relationship between COX-2 specific inhibitors and hypertension.
Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Celecoxib; Cyclooxygenase Inhibitors; Female; Hum | 2004 |
[Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2004 |
Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Celecoxib; C | 2005 |
Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension.
Topics: Animals; Blood Pressure; Blood Vessels; C-Reactive Protein; CD8-Positive T-Lymphocytes; Celecoxib; C | 2005 |
Blood pressure in Native Americans switched from celecoxib to rofecoxib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arizona; Blood Pressure; Ce | 2005 |
COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2005 |
Eosinophilic fasciitis in a 57-year-old Japanese-American woman.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diagnosis, Differential; Eosinophilia; Fasciitis | 2007 |
New diagnosis of hypertension among celecoxib and nonselective NSAID users: a population-based cohort study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cycloox | 2007 |
Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Topics: Animals; Aspirin; Blood Pressure; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 In | 2008 |
Celecoxib and hypertension-insights from the effect of celecoxib on restenosis after coronary angioplasty with a taxus stent trial.
Topics: Angioplasty, Balloon, Coronary; Blood Pressure; Celecoxib; Coronary Artery Disease; Coronary Resteno | 2008 |
Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence.
Topics: Animals; Aorta, Thoracic; Blood Pressure; Celecoxib; Cell Adhesion; Cyclooxygenase 2; Cyclooxygenase | 2000 |
Cardiovascular events and COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C | 2001 |